PMS Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds
Primary Purpose
Wound
Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Silver II Non-Woven Dressing
Sponsored by
About this trial
This is an interventional treatment trial for Wound
Eligibility Criteria
Inclusion Criteria:
- Males or females, age 18 years or above. (Females must not be pregnant and if of reproductive age should be using contraception).
- Patients who are able to understand and give informed consent to take part in the study.
- Have one or more of the following: Pressure ulcer, Leg ulcer, Diabetic ulcers, Post-operative surgical wounds, Graft and donor sites, Cavity wounds, Trauma wounds (dermal lesions, trauma injuries or incisions) and superficial and partial thickness burn wounds that are infected, or are at high risk of infection , that are moderate to heavy levels of exudate.
- For Partial Thickness Second Degree Burns that require grafting - only those grafts with single thickness mesh grafts that have X % epithelialization will be enrolled [Note: % epithelization to be added once sites/countries are chosen as this is specific to the territory where the Silver II Non Woven Dressing study is likely to be performed].
Exclusion Criteria:
- Patients who are known to be non-compliant with medical treatment,
- Patients who are known to be sensitive to any of the device components
- Subject is pregnant or actively breastfeeding;
- Subject has a known sensitivity to Silver;
- Life expectancy of <6 months;
- Maximum burn area of > 20% total body area. Using the rule of nines assessment tool. [Note: criteria to be confirmed once sites/countries are chosen]
- Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study;
Sites / Locations
- Queen Elizabeth the Queen Mother HospitalRecruiting
- HMC HealthRecruiting
- Nottingham University Hospitals City Hospital, Hucknall Rd,Recruiting
- University Hospitals Plymouth NHS Trust - Derriford HospitalRecruiting
- Royal Berkshire NHS Foundation TrustRecruiting
- Berkshire Healthcare NHS Foundation 57-59 Bath Rd,Recruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Assigned Intervention
Arm Description
Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
Outcomes
Primary Outcome Measures
Effectiveness of the Silver II Non-Woven Dressing
Effectiveness (performance) of the Silver II Non-Woven Dressing will be evaluated for efficacy success according to the following success criteria:
Reduction in signs and symptoms of infection from baseline as defined as
The change from the Investigator's opinion of infection being present to no longer being present, or If the Investigator determines infection is still present there is improvement in severity of at least two.
Secondary Outcome Measures
User satisfaction with the Silver II Non-Woven Dressing.
To establish clinician and user satisfaction Clinician satisfaction with the device (conformability & ease of use) this will be assessed using a Likert type scale. (Very satisfied, Satisfied and not Satisfied)
Full Information
NCT ID
NCT05045430
First Posted
September 7, 2021
Last Updated
July 21, 2023
Sponsor
Advanced Medical Solutions Ltd.
Collaborators
NAMSA
1. Study Identification
Unique Protocol Identification Number
NCT05045430
Brief Title
PMS Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds
Official Title
Post Market Surveillance Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 13, 2022 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Advanced Medical Solutions Ltd.
Collaborators
NAMSA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Post Market Surveillance Study to confirm the safety and performance of Silver II Non-Woven Dressing in Chronic and Acute Wounds
Detailed Description
The design of the study is an open-label, multicentre, single arm clinical trial in subjects with moderate to heavily exuding infected chronic and acute wounds consisting of Pressure ulcers, Leg ulcers, Diabetic ulcers, Post-operative surgical wounds, Graft and donor sites, Cavity wounds, Trauma wounds (dermal lesions, trauma injuries or incisions) and Superficial and partial thickness burns. The performance data from this study will support clinically meaningful rates of successful improvement in the signs and symptoms of infection, without re-infection during 6-week treatment and follow up period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Assigned Intervention
Arm Type
Experimental
Arm Description
Subjects will undergo treatment of their chronic or acute wound as indicated in the instructions for use with Silver II Non-Woven Dressing
Intervention Type
Device
Intervention Name(s)
Silver II Non-Woven Dressing
Intervention Description
Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.
Subjects will be evaluated as follows:
Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.
The assessment of the presence and reduction of the signs and symptoms of Infection.
Primary Outcome Measure Information:
Title
Effectiveness of the Silver II Non-Woven Dressing
Description
Effectiveness (performance) of the Silver II Non-Woven Dressing will be evaluated for efficacy success according to the following success criteria:
Reduction in signs and symptoms of infection from baseline as defined as
The change from the Investigator's opinion of infection being present to no longer being present, or If the Investigator determines infection is still present there is improvement in severity of at least two.
Time Frame
No worsening of any signs/ symptoms of infection at 6 weeks or if infection resolved prior to 6 weeks, that no new evidence of infection occurred during the 6 week treatment follow up.
Secondary Outcome Measure Information:
Title
User satisfaction with the Silver II Non-Woven Dressing.
Description
To establish clinician and user satisfaction Clinician satisfaction with the device (conformability & ease of use) this will be assessed using a Likert type scale. (Very satisfied, Satisfied and not Satisfied)
Time Frame
immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females, age 18 years or above. (Females must not be pregnant and if of reproductive age should be using contraception).
Patients who are able to understand and give informed consent to take part in the study.
Have one or more of the following: Pressure ulcer, Leg ulcer, Diabetic ulcers, Post-operative surgical wounds, Graft and donor sites, Cavity wounds, Trauma wounds (dermal lesions, trauma injuries or incisions) and superficial and partial thickness burn wounds that are infected, or are at high risk of infection , that are moderate to heavy levels of exudate.
For Partial Thickness Second Degree Burns that require grafting - only those grafts with single thickness mesh grafts that have X % epithelialization will be enrolled [Note: % epithelization to be added once sites/countries are chosen as this is specific to the territory where the Silver II Non Woven Dressing study is likely to be performed].
Exclusion Criteria:
Patients who are known to be non-compliant with medical treatment,
Patients who are known to be sensitive to any of the device components
Subject is pregnant or actively breastfeeding;
Subject has a known sensitivity to Silver;
Life expectancy of <6 months;
Maximum burn area of > 20% total body area. Using the rule of nines assessment tool. [Note: criteria to be confirmed once sites/countries are chosen]
Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Danielle King, BSc (hons)
Phone
07711712990
Email
danielle.king@admedsol.com
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca Forder, BA (Hons)
Phone
01606 545677
Email
Rebecca.forder@admedsol.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jessica Evans, MBBS MRCS
Organizational Affiliation
Queen Elizabeth Queen Mother Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Elizabeth the Queen Mother Hospital
City
Margate
State/Province
Kent
ZIP/Postal Code
CT9 4AN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Research and Innovation
Email
ekhuft.researchandinnovation@nhs.net
First Name & Middle Initial & Last Name & Degree
Jessica Evans
Facility Name
HMC Health
City
London
ZIP/Postal Code
TW3 3ET
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Ms Green
Phone
07590528952
Email
Melissa.green@nhs.net
First Name & Middle Initial & Last Name & Degree
Ivor Dr Singh, MD MRCGP
Facility Name
Nottingham University Hospitals City Hospital, Hucknall Rd,
City
Nottingham
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hobbs
Email
jo.hobbs@nuh.nhs.uk
First Name & Middle Initial & Last Name & Degree
Skaria Alexander
Facility Name
University Hospitals Plymouth NHS Trust - Derriford Hospital
City
Plymouth
ZIP/Postal Code
PL6 8DH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Email
plh-tr.rd-office@nhs.net
First Name & Middle Initial & Last Name & Degree
Alexandra Bishop
Facility Name
Royal Berkshire NHS Foundation Trust
City
Reading
ZIP/Postal Code
RG1 5AN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Garfield
Email
rebecca.garfield@royalberkshire.nhs.uk
First Name & Middle Initial & Last Name & Degree
Keith Hilston
Facility Name
Berkshire Healthcare NHS Foundation 57-59 Bath Rd,
City
Reading
ZIP/Postal Code
RG30 2BA
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Blackman
Email
sarra.blackman@berkshire.nhs.uk
First Name & Middle Initial & Last Name & Degree
Mikyung Bailey
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PMS Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds
We'll reach out to this number within 24 hrs